BIVI logo

BioVie Inc.

BIVI
Healthcare|Biotechnology|US
$1.33
+0.12 (+9.92%)
DCF Value
$1200941.90
Tangible Book / Share
$0.75
Cash / Share
$0.94
Financing Filings (last 12 months)
9
Shelf registrations / offering prospectuses — latest Nov 5, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Nov 4, 2026 · GlobeNewsWire
BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026
Nov 2, 2026 · GlobeNewsWire
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH's RECOVER-TLC Third Annual Workshop
Oct 26, 2026 · GlobeNewsWire
BioVie Presents Data on Bezisterim in Parkinson's Disease at the 2026 American Neurological Association Annual Meeting
Oct 20, 2026 · GlobeNewsWire
BioVie to Present New Bezisterim Findings in Parkinson's Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
Oct 14, 2026 · GlobeNewsWire
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Sep 15, 2026 · GlobeNewsWire
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
Sep 14, 2026 · GlobeNewsWire
BioVie Announces Update to Parkinson's Phase 3 Development Program
Sep 8, 2026 · GlobeNewsWire
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Aug 31, 2026 · GlobeNewsWire

SEC Filings (64)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 202610-QQuarterly reportDocumentIndex
Nov 6, 20268-KMaterial eventDocumentIndex
Nov 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 5, 2026424B5Offering prospectusDocumentIndex
Nov 5, 2026424B5Offering prospectusDocumentIndex
Nov 4, 2026424B5Offering prospectusDocumentIndex
Sep 28, 2026DEF 14AProxy / shareholder voteDocumentIndex
Sep 14, 20268-KMaterial eventDocumentIndex
Sep 14, 2026424B5Offering prospectusDocumentIndex
Sep 3, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 19, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 14, 2026S-1/AIPO / offering registrationDocumentIndex
Aug 13, 202610-KAnnual reportDocumentIndex
Aug 7, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 7, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 7, 2026FWPDocumentIndex
Aug 6, 2026FWPDocumentIndex
Aug 6, 2026FWPDocumentIndex
Aug 6, 2026S-1/AIPO / offering registrationDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jul 31, 2026S-1/AIPO / offering registrationDocumentIndex
Jul 17, 2026S-1IPO / offering registrationDocumentIndex
Jun 29, 2026EFFECTDocumentIndex
Jun 18, 2026S-3Shelf registrationDocumentIndex
May 11, 202610-QQuarterly reportDocumentIndex
Mar 25, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Feb 6, 202610-QQuarterly reportDocumentIndex
Nov 25, 2025S-8Employee stock planDocumentIndex
Nov 18, 2025EFFECTDocumentIndex
Nov 13, 20258-KMaterial eventDocumentIndex
Nov 12, 20258-KMaterial eventDocumentIndex
Nov 10, 202510-QQuarterly reportDocumentIndex
Oct 6, 2025POS AMDocumentIndex
Oct 6, 2025POS EXDocumentIndex
Oct 6, 2025424B3Offering prospectusDocumentIndex
Sep 25, 2025DEF 14AProxy / shareholder voteDocumentIndex
Aug 15, 202510-KAnnual reportDocumentIndex
Aug 11, 20258-KMaterial eventDocumentIndex
Aug 8, 2025424B5Offering prospectusDocumentIndex
Aug 7, 2025EFFECTDocumentIndex